Despite the development of PD-L1-informed CRC treatment, including novel immunotherapies and targeted therapies, the desired overall survival rates of patients with CRC have not yet been achieved (Lu, Xin & Wang, 2019). This evidence concerns the gene CD274 and colorectal carcinoma.